About Cilcare

CILCARE is dedicated to harnessing its expertise in auditory sciences to more precisely define, detect and treat auditory-related diseases

Leveraging a decade of R&D in inner ear therapeutics, CILcare has developed a groundbreaking approach to translate advanced science in hearing disorders coupled with auditory signature and real-world evidence into novel therapies.

While hearing loss has been ranked as the 3^rd most common cause of YLDs, more and more studies have highlighted linking to other chronic disabling conditions such as Alzheimer’s disease, diabetes, cardiovascular diseases and many more. A growing body of research has shown that hearing loss confers an independent risk of dementia, which could be a harbinger of declining cognitive function.

In less than a decade, CILcare has generated a massive set of preclinical auditory data on various auditory models. Combined with real-world data, we believe that these auditory digital signatures will be at the heart to develop new targeted therapies of age-related hearing disorders.

CILCARE has also been a catalyst for drug development in hearing disorders since its inception in 2014.  Established in Boston, Paris, and Montpellier, CILcare provides its smart R&D platform as a research-for-hire to the top hearing research companies, pharmaceutical, medical devices and veterinary industries, as well as academic institutions across the US, Europe and Asia.

Our state-of-the-art laboratories and research experts in otology and neurosciences enables us to offer fully customizable and comprehensive R&D program including pharmacokinetics, preclinical efficacy, and GLP ototoxicity studies.

A trusted partner with the ambition to provide effective treatments to millions of patients suffering from ear diseases, on a global scale, join us as we fight for this cause: The care of this extraordinary sense: hearing.